Skip to content
NYSE · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · LARGE CAP

Cardinal Health Inc. CAH

19 fiscal years on record · USD · FY2025 reported · SEC filings only
18 YEARS OF DIVIDEND GROWTH
$254.2B
▲ 14.2% YoY
$1.7B
▲ 9.8% YoY
$4.5B
▲ 144.6% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Cardinal Health provides medical products and pharmaceuticals to hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. Its Cardinal Health brand products are sold directly or through third-party distributors in the United States, Canada, Europe, Asia and other markets. As of June 30, 2026 it had approximately 63,900 employees globally, of which approximately 18,100 are based outside the United States. Its largest customer, CVS Health, accounted for 28 percent of fiscal 2026 revenue. Taken together, the five largest customers, CVS Health among them, accounted for 43 percent of that year's revenue. Sales to members of the two group purchasing organizations with which it holds its principal GPO relationships accounted for 29 percent of revenue in fiscal 2026. In fiscal 2026, products obtained from its five largest suppliers generated an aggregate of 39 percent of revenue, and its largest supplier's products accounted for approximately 13 percent. Red Oak Sourcing, LLC, a generic pharmaceutical sourcing venture with CVS Health, negotiates generic pharmaceutical supply contracts on behalf of both companies.

Written from the business description in Cardinal Health, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 11 August 2026. Every sentence was checked against that document before publication.

Growth

USD 254.2B
Revenue, FY2025 · full 19-year series below
Revenue $B Net income $B
FY2025 · Revenue 254.2 · Net income 1.7
100B200B
2007201020132016201920222025
Compound annual growth
+7.4%
+9.4%
+7.7%
+6.2%
+73.2%
+22.9%
+1.8%
+3.9%
+79.0%
+28.3%
+5.3%
+6.7%
+1.0%
+1.0%
+2.8%
+6.6%
−9.9%
+19.1%
+4.7%
+9.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +9.4% a year over the five years to FY2025 — but profit grew faster: net income at +22.9%, earnings per share at +28.3%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

1 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 1.0% · Net 0.7%
1%2%-1%-2%
200720162025
ROE
FY2020 · ROE 34.1%
10%20%30%-50%
200720162025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: 19%.

Cash & shareholders

USD 1.8B
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 4.5
2B4B
200720162025
Net buybacks $B Dividends $B
FY2025 · Dividends 0.5 · Net buybacks 1.4
1B2BDividendsNet buybacks
2007201020132016201920222025

USD 491.0M in dividends and USD 1.4B in buybacks — 108% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 57.3B
EquityUSD -2.9B
CashUSD 4.9B
Gross debtUSD 7.0B
Net debtUSD 2.1B
Current ratio0.88×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
CAH, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B254.2222.6226.8205.0181.3162.5152.9145.5136.8130.0121.5102.591.1101.1107.6102.698.596.087.4
Operating income $B2.62.31.20.8−0.60.5−4.12.10.12.12.52.21.91.01.81.51.31.31.4
EBITDA $B3.63.12.01.40.11.3−3.23.11.22.83.12.62.31.42.11.81.61.51.6
Income tax $B0.50.50.30.30.2−0.3−0.10.4−0.50.60.80.80.60.60.60.60.60.40.4
Net income $B1.71.60.90.3−0.90.6−3.71.40.31.31.41.21.20.31.11.00.61.21.3
Free cash flow $B4.51.93.32.42.82.01.62.42.40.82.52.22.31.50.91.11.91.0◌
EPS, diluted $7.236.453.451.26−3.372.08−12.614.530.814.034.323.623.380.973.062.721.773.18◌
Dividend / sh $2.042.022.001.981.961.941.921.911.851.801.551.371.211.020.860.780.700.560.48
Payout %293259159−6094−1542227453638361062829391713
ROE %—————34.1−91.122.04.019.322.319.218.85.517.717.29.214.016.8

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 93 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Two checks were skipped: the balance sheet is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityWholesale-Drugs, Proprietaries & Druggists' Sundries
Listed onNYSE
Incorporated inOhio
Fiscal year endsJune 30
Data on record since2007

Share this section

Download image